Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world demographics and survival outcomes of patients in England with advanced or recurrent endometrial cancer by mismatch repair status.

Gynecologic oncology reports·2026

Same author

Efficient in vivo assembly of DNA encoded polyvalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancer.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Journal of gynecologic oncology·2026

Same author

Ciliated Cells Drive Critical STING-Mediated Tumor Suppression in the Fallopian Tube Epithelium.

Cancer research·2026

Same author

Spatial integration of protein and chromosomal states reveals early copy number changes and genotype-associated immune neighborhoods in serous ovarian cancer evolution.

Cancer discovery·2026

Same author

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Gynecologic oncology·2026

Search research articles

Related Experiment Video

Updated: Aug 19, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Targeting NaPi2b in ovarian cancer.

Susana Banerjee¹, Ronny Drapkin², Debra L Richardson³

¹Royal Marsden NHS Foundation Trust, London, United Kingdom.

Cancer Treatment Reviews

|November 29, 2022

Summary

Novel biomarkers like NaPi2b are crucial for ovarian cancer treatment. This sodium-dependent phosphate transporter shows promise for targeted therapies and patient selection, especially in platinum-resistant cases.

Keywords:

Antibody-drug conjugate Biomarker Ovarian cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Related Experiment Videos

Last Updated: Aug 19, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Area of Science:

Oncology
Biomarker Discovery
Molecular Imaging

Background:

Ovarian cancer treatment relies heavily on platinum-based chemotherapy, with limited options for platinum-resistant disease.
Novel biomarkers are essential for developing targeted therapies and improving patient selection in ovarian cancer.
NaPi2b, a sodium-dependent phosphate transporter, is upregulated in ovarian tumors with limited expression in normal tissues.

Purpose of the Study:

To review the literature supporting NaPi2b as a biomarker for ovarian cancer treatment and patient selection.
To discuss the potential of NaPi2b for therapeutic targeting in ovarian cancer.
To outline future research directions for NaPi2b biomarker and therapeutic development.

Main Methods:

Literature review of preclinical and clinical studies on NaPi2b in ovarian cancer.
Analysis of NaPi2b expression in ovarian tumors and normal tissues.
Evaluation of NaPi2b-targeting antibodies and antibody-drug conjugates in preclinical and clinical settings.

Main Results:

NaPi2b is expressed in select cancers, including ovarian cancer, making it a promising biomarker.
Preclinical studies demonstrate NaPi2b's utility for tumor mapping and therapeutic targeting.
Phase 1 and 2 clinical trials indicate successful detection of NaPi2b in patient biopsies and therapeutic responses to NaPi2b-targeting agents.

Conclusions:

NaPi2b is a viable biomarker candidate for ovarian cancer treatment and patient selection.
Targeting NaPi2b with antibody-drug conjugates shows therapeutic potential in ovarian cancer.
Further research and clinical validation are necessary to advance NaPi2b-based strategies for ovarian cancer.